| 55130-9 |
Physical restraints used in chair or out of bed |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Physical restraints used in chair or out of bed |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55130-9 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Pan; Panel; Panl; Pnl; Point in time; Random; Survey; SURVEY.MDS |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 55131-7 |
Number of D of rehabilitative or restorative techniques |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Number of days of rehabilitative or restorative techniques |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55131-7 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
# days of rehabilitative or restorative techniques; Dextro; No; Num; Pan; Panel; Panl; Pnl; Point in time; Random; Survey; SURVEY.MDS |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 55132-5 |
Number of D of rehabilitative or restorative training and skill practice |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Number of days of rehabilitative or restorative training and skill practice |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55132-5 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
# days of rehabilitative or restorative training and skill practice; Dextro; No; Num; Pan; Panel; Panl; Pnl; Point in time; Random; Survey; SURVEY.MDS |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 55133-3 |
Influenza virus A hemagglutinin cDNA |
Prid |
Isolate |
Pt |
Nom |
Probe.amp.tar |
|
ACTIVE |
Influenza virus A hemagglutinin cDNA [Identifier] in Isolate by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Type A subtype H1, Type A subtype H2, Type A subtype H3, Type A subtype H5, Type A subtype H7, Type A subtype H9, Type A, Unable to determine subtype |
|
|
|
|
|
MICRO |
|
55133-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUAV HA cDNA Islt NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Avian influenza; Bird flu; complementary DNA; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV HA; FLUV; Fowl plague; HA; ID; Identity or presence; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Islt; Isol; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 55134-1 |
Influenza virus A neuraminidase RNA |
Prid |
Isolate |
Pt |
Nom |
Probe.amp.tar |
|
DISCOURAGED |
Influenza virus A neuraminidase RNA [Identifier] in Isolate by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Type A subtype N1 Type A subtype N2 Unable to determine subtype |
|
|
|
|
|
MICRO |
|
55134-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUAV NA RNA Islt NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV NA; FLUV; Fowl plague; ID; Identity or presence; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Islt; Isol; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NA; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 55135-8 |
BCR-ABL1 kinase domain targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
BCR-ABL1 kinase domain mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
55135-8 |
|
Molgen |
|
|
Both |
|
|
|
0 |
BCR/ABL1 kinase domain Mut Anl Bld/T |
|
|
|
N |
|
ABL; ALL; BCR/ABL1 kinase domain; BCR1; Blood; Breakpoint cluster region; Chronic myeloid leukemia; CML; D22S11; D22S662; Genetics; Hematology; Heme; Heredity; Heritable; Identity or presence; Inherited; JTK7; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; p150; PCR; PHL; Point in time; Random; Tissue; Tissue, unspecified; v-abl Abelson murine leukemia viral oncogene homolog 1; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for specific mutations as described in the LOINC User Guide under the Molecular Genetics section. |
0 |
| 55136-6 |
Penicillin.parenteral |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Penicillin Parenteral [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
55136-6 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Penicillin Parenteral Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; PCN; Pen; Penicillin Parenteral; Penicilloyl; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Wycillin |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 55137-4 |
Penicillin.parenteral |
Susc |
Isolate.meningitis |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Penicillin Parenteral [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
55137-4 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Penicillin Parenteral Islt.mening MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Islt.mening; Isol; Mening; Minimum inhibitory concentration; PCN; Pen; Penicillin Parenteral; Penicilloyl; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Wycillin |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Moved "meningitis" from Component to System to more accurately represent that the concept means antimicrobial susceptibility result for a patient with meningitis rather than susceptibility result for a meningitis form of the antibiotic. |
0 |
| 55138-2 |
Cortisol^post dose dexamethasone PO overnight |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --post dose dexamethasone PO overnight |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ug/dL |
Performed by Quest Diagnostics Test # 6921 |
|
|
|
|
|
CHAL |
|
55138-2 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis p Dex overnight SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; After; c350; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Decadron; Dexameth; Dexone; F; Hexadrol; hydrocortisone; Level; Mass concentration; p Dex; p Dex overnight; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.27 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 55139-0 |
SCN5A gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
SCN5A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
http://www.pgxhealth.com/genetictests/familion/index.cfm |
|
|
|
|
|
MOLPATH.MUT |
|
55139-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SCN5A gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; cardiac sodium channel alpha subunit; CDCD2; CMD1E; CMPD2; Document; Finding; Findings; Genetics; HB1; HB2; HBB; HBBD; Heredity; Heritable; HH1; ICCD; Inherited; IVF; LQT3; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; NAV1.5; PCR; PFHB1; Point in time; Random; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; sodium channel, voltage gated, type V alpha subunit; SSS1; Tissue; Tissue, unspecified; VF1; Voltage-gated sodium channel subunit alpha Nav1.5; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 5514-5 |
CD63 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD63 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5514-5 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD63 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; gp55; Granulophysin; LAMP-3; Leukocytes; LIMP; lysosomal-membrane-associated glycoprotein 3; ME491; Melanoma-associated antigen; MLA1; Neuroglandular antigen; NGA; Point in time; PTLGP40; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 55140-8 |
Vaccine Adverse Event Reporting System panel |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Vaccine Adverse Event Reporting System (VAERS) panel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.VACCIN |
|
55140-8 |
|
|
|
|
|
|
|
|
0 |
VAERS Pnl |
|
|
|
N |
|
AE; Pan; PANEL.VACCIN; Panl; Pnl; Point in time; Random; VAERS Pnl |
2.27 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 55141-6 |
Fc epsilon RI + RII Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Fc epsilon RI + RII Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
http://www.ibtlabs.com/diagnostic_testing_services/test_directory.asp?q=2103 Range 0-50 REFERENCE HIGH: 9.9 |
|
|
|
|
|
SERO |
|
55141-6 |
|
|
|
|
Both |
|
|
|
0 |
Fc epsilon RI + RII Ab Ser-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Chronic Urticaria Index; CU Index; Fc epsilon R1; Fce; FceRI; High affinity IgE receptor; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.73 |
2.27 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 55142-4 |
Cache valley virus RNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Cache valley virus RNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
55142-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
CVV RNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; CVV; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Orthobunyaviruses; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 55143-2 |
California serogroup virus RNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
California serogroup RNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Detected, Not Detected |
|
|
|
|
|
MICRO |
|
55143-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
CSGV RNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; CA; Calif; CSGV; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 55144-0 |
Powassan virus RNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Powassan virus RNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
55144-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
POWV RNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; POWV; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 55145-7 |
Saint Louis encephalitis virus RNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Saint Louis encephalitis virus RNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
55145-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
SLEV RNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Enc; Enceph; Encephalomyelitis; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; SLE virus; SLEV; Spec; St Louis; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 55146-5 |
Familial long QTS syndrome gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
Familial long QTS syndrome gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
http://www.pgxhealth.com/genetictests/familion/index.cfm |
|
|
|
|
|
MOLPATH.MUT |
|
55146-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
Familial LQTS Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; Familial LQTS; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 55147-3 |
t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript |
NRto |
Bld/Tiss |
Pt |
Qn |
Molgen |
|
ACTIVE |
t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
MOLPATH.TRNLOC |
|
55147-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
t(ABL1,BCR)p210/control Bld/T |
|
|
|
N |
|
ABL; ABL1; ABL1 transcript; ALL; bcr/abl; BCR1; bcr-abl1; Blood; Breakpoint cluster region; Chronic myeloid leukemia; CML; control gene; D22S11; D22S662; DNA; e13a2; e14a2; gene fusion; gene translocation; Genetics; Heredity; Heritable; Inherited; JTK7; major breakpoints; Mbr; Mcr; minor breakpoints; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.TRANSLOCATION; Number ratio; p150; p210; PCR; Ph chromosome; Philadelphia chromosome; PHL; Point in time; QNT; Quan; Quant; Quantitative; Random; RNA; T prime; t(9,22)(ABL1,BCR) gene translocation; t(9,22)(ABL1,BCR) p210 gene translocation; t(9,22)(ABL1,BCR) Translocation; t(9,22)(q34,q11); t(9,22)(q34.1,q11); t(9;22)(ABL1,BCR); t(ABL1,BCR)b2a2; t(ABL1,BCR)p210; Tissue; Tissue, unspecified; translocation; v-abl Abelson murine leukemia viral oncogene homolog 1; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.27 |
|
|
|
|
|
|
|
% |
|
|
Updated Component part to harmonize with ISCN guidelines and current LOINC nomenclature. |
0 |
| 55148-1 |
BCR-ABL1 b2a2+b3a2 fusion transcript |
Arb |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
DEPRECATED |
Deprecated fusion transcript [Presence] in Blood or Tissue by Molecular genetics method |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.TRNLOC |
|
55148-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
Deprecated Bld/T Ql |
|
|
|
N |
|
ABL; ALL; Arbitrary; BCR1; Blood; Breakpoint cluster region; Chronic myeloid leukemia; CML; D22S11; D22S662; DNA; gene fusion; gene translocation; Genetics; Heredity; Heritable; Inherited; JTK7; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.TRANSLOCATION; Ordinal; p150; PCR; PHL; Point in time; QL; Qual; Qualitative; Random; RNA; Screen; Tissue; Tissue, unspecified; translocation; v-abl Abelson murine leukemia viral oncogene homolog 1; WB; Whole blood; Whole blood or Tissue |
2.4 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 55149-9 |
BCR-ABL1 e1a2 fusion protein |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
BCR-ABL1 e1a2 fusion protein [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
55149-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
e1a2 Bld/T Ql |
|
|
|
N |
|
ABL; ALL; BCR1; Blood; Breakpoint cluster region; Chronic myeloid leukemia; CML; D22S11; D22S662; Genetics; Hematology; Heme; Heredity; Heritable; Inherited; JTK7; Molecular genetics; Molecular pathology; MOLPATH; Ordinal; p150; PCR; PHL; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; v-abl Abelson murine leukemia viral oncogene homolog 1; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Changed component from BCR-ABL1 e1a2 fusion transcript/ABL1 transcript; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 5515-2 |
CD64 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD64 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5515-2 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD64 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; Fc gamma receptor I; Fc gamma RI; FC gammaRI; FCR I; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 55150-7 |
Anaplasma phagocytophilum Ab.IgG & IgM panel |
- |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Anaplasma phagocytophilum IgG and IgM panel - Serum Qualitative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
55150-7 |
|
|
|
|
Order |
|
|
|
0 |
A phagocytoph IgG+IgM Pnl Ser |
|
|
|
N |
|
A phagocytoph IgG+IgM Pnl; E equi; E phagocytophila; Ehrlichia equi; Ehrlichia phagocytophila; HGE; Human granulocytic ehrlichiosis; ID; Immune globulin G; Immune globulin M; Immunoglobulin G; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 55151-5 |
Aldosterone & renin activity panel |
- |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone and renin activity panel - Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
55151-5 |
|
|
|
|
Order |
|
|
|
0 |
Aldosterone + RA + ARR Pnl Plas |
|
|
|
N |
|
Activ; Actvty; Aldosterone + RA + ARR Pnl; Angiotensin forming enzyme; Angiotensinogenase; Chemistry; Endocrine; Endocrinology; Movements; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; UniversalLabOrders |
2.73 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 55152-3 |
Amiodarone & Desethylamiodarone panel |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amiodarone and Desethylamiodarone panel [Mass/volume] - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
55152-3 |
|
|
|
|
Order |
|
|
|
0 |
Amiodarone + Deseth Pnl SerPl-mCnc |
|
|
|
N |
|
Amiodarone + Deseth Pnl; Amiodarone metabolite; Amiodarone+Deseth; Cordarone; DEA; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Noramiodarone; Pacerone; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
